Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020
Since the discovery of RET fusion–positive (RET+) NSCLC around late 2011 to early 2012, clinical trials of multikinase inhibitors and highly potent and selective RET tyrosine kinase inhibitors have indicated that RET fusion is an actionable oncogenic driver in NSCLC. There seems to be a differential...
में बचाया:
| मुख्य लेखकों: | , |
|---|---|
| स्वरूप: | Revisão |
| भाषा: | अंग्रेज़ी |
| प्रकाशित: |
2020
|
| ऑनलाइन पहुंच: | https://doi.org/10.1016/j.jtocrr.2020.100037 http://www.jtocrr.org/article/S2666364320300424/pdf |
| टैग: |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|